Changes in Control of Registrant. The disclosures set forth in the Introductory Note and Items 2.01, 3.01, 3.03, 5.02 and 5.03 of this Current Report on Form 8-K are incorporated herein by reference. As a result of the consummation of the Merger, a change in control of the Company occurred and the Company became a wholly owned subsidiary of Parent. The aggregate consideration paid by Parent in connection with the Merger was approximately $10.0 billion, which was funded using a combination of…

Director: The filing describes the complete replacement of the board and officers as a mandatory consequence of a merger, which is a structural corporate event rather than a voluntary executive departure or routine election.

Termination of a Material Definitive Agreement. In connection with the consummation of the Merger, effective immediately prior to the Effective Time, the Company terminated the Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan. In connection with the consummation of the Merger, effective as of the Effective Time, the Company terminated the Sales Agreement, dated June 21, 2024, by and among the Company, SVB Leerink LLC and Cantor Fitzgerald & Co. In addition, effective as of th…

Completion of Acquisition or Disposition of Assets. The disclosures set forth in the Introductory Note of this Current Report on Form 8-K are incorporated herein by reference.

Material Modification to Rights of Security Holders. The disclosures set forth in the Introductory Note and Items 2.01, 3.01, 5.01 and 5.03 of this Current Report on Form 8-K are incorporated herein by reference. As a result of the Merger, each share of Company Common Stock issued and outstanding immediately prior to the Effective Time, except as described in the Introductory Note, was converted at the Effective Time into the right to receive the Merger Consideration in accordance with the te…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The disclosures set forth in the Introductory Note of this Current Report on Form 8-K are incorporated herein by reference. In connection with the consummation of the Merger, the Company requested that the Nasdaq Stock Market LLC (“ Nasdaq ”) suspend trading in the Company Common Stock effective prior to the opening of trading on the Closing Date. On the Closing Date, following the Effective T…

Other Events. As previously announced, on July 6, 2026, Crinetics Pharmaceuticals, Inc., a Delaware corporation (“Crinetics” or the “Company”), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“Vertex”), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Vertex (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) pursuant to which Merger Sub will be merged with and into Crinetics (the “Merger”), with Crinetics…

Other Events. As previously announced, on July 6, 2026, Crinetics Pharmaceuticals, Inc., a Delaware corporation (“Crinetics” or the “Company”), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“Vertex”), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Vertex (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) pursuant to which Merger Sub will be merged with and into Crinetics (the “Merger”), with Crinetics…

Results of Operations and Financial Condition. On August 3, 2026 , Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) issued a press release reporting its financial results for the period ended June 30, 2026. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated herein, including the press release furnished as Exhibit 99.1, shall not be dee…

of this Current Report on Form 8-K is incorporated by reference herein. Cautionary Notice Regarding Forward-Looking Statements This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 related to the Company, Parent and the transactions contemplated by the Merger Agreement (the “ Transactions ”) that are subject to risks, uncertainties and other factors. While the Company believes the forward-looking statem…

The filing does not provide specific information about a management change, director election, or officer appointment.

Other Events. On July 6, 2026, the Company and Parent issued a joint press release announcing the execution of the Merger Agreement. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Cautionary Notice Regarding Forward-Looking Statements This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 related to the Company, Parent and the Transactions that are…

Entry into a Material Definitive Agreement Merger Agreement On July 6, 2026, Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“ Parent ”), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”). Subject to the terms of the Merger Agreement, Merger Sub will be merged with and int…

Results of Operations and Financial Condition. On May 7, 2026 , Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) issued a press release reporting its financial results for the period ended March 31, 2026. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed “f…

Chief Development and Operating Officer — Jeff Knight: Mr. Knight resigned from his position and entered into a consulting agreement with the company.

Chief Development and Operating Officer — Jeff Knight: Mr. Knight resigned to pursue another opportunity.

Changes in Registrant's Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm On February 27, 2026, the Audit Committee (the "Audit Committee") of the Board of Directors of Crinetics Pharmaceuticals, Inc. (the "Company") approved the dismissal of BDO USA, P.C. ("BDO") as the Company’s independent registered public accounting firm. The reports of BDO on the Company's consolidated financial statements for the fiscal years ended December 31, 2025 and 2024 did not…

Results of Operations and Financial Condition. On February 26, 2026 , Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) issued a press release reporting its financial results for the period ended December 31, 2025. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be…

Chief Development and Operating Officer — Jeff Knight: Mr. Knight's title was changed to reflect an expansion of his responsibilities.

Results of Operations and Financial Condition. On January 13, 2026, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) reiterated certain previously announced preliminary and unaudited financial and operating results for the fourth quarter ended December 31, 2025, including that Crinetics expects to report that it generated net product revenue from PALSONIFY TM (paltusotine) of over $5.0 million for the three months ended December 31, 2025. Crinetics’ audited financial statements…

Other Events. On January 6, 2026, Crinetics Pharmaceuticals, Inc. (“Crinetics” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and J.P. Morgan Securities LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale of 7,620,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). In addition, under the terms of the Under…

Results of Operations and Financial Condition. On January 5, 2026, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) announced certain preliminary and unaudited financial and operating results for the fourth quarter ended December 31, 2025, including that Crinetics expects to report that it generated net product revenue from PALSONIFY TM (paltusotine) of over $5.0 million for the three months ended December 31, 2025. Crinetics’ audited financial statements for the year ended Dece…

Chief Medical and Development Officer — Dana Pizzuti, M.D.: Dr. Pizzuti will step down from her position as Chief Medical and Development Officer but will continue in an advisory role.

Results of Operations and Financial Condition. On November 6, 2025 , Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) issued a press release reporting its financial results for the period ended September 30, 2025. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be…

Other Events. On September 25, 2025, the FDA approved PALSONIFY for the first-line treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. PALSONIFY, a selectively-targeted somatostatin receptor type 2 nonpeptide (“SST2”) agonist, is now the first once-daily, oral treatment approved for adults with acromegaly. This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities A…